-
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Su, Y.-J., Kramer, A. M., Hamilton, M. P., Agarwal, N., Srinagesh, H. K., Baird, J. H., Sahaf, B., Kuo, A., Ehlinger, Z. J., Desai, M. H., Rietberg, S. P., Tunuguntla, R., Patel, S., Chinnasamy, H., Gkitsas-Long, N., Klysz, D. D., Brown, A. K., Bharadwaj, S., Dahiya, S. & Smith, M. & 6 others, , 1 Apr 2025, In: Cancer discovery. 15, 4, p. 733-747 15 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia
Srinagesh, H., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A., Kramer, A. M., Arai, S., Bharadwaj, S., Dahiya, S., Hosoya, H., Johnston, L., Kennedy, V. & Liedtke, M. & 16 others, , 17 Oct 2024, In: Blood. 144, 16, p. 1689-1698 10 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
CARdinal-22 Investigator group, 27 Jul 2024, In: Lancet. 404, 10450, p. 353-363 11 p.Research output: Contribution to journal › Article* › Academic › peer-review
- All publications